Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1991 1
1992 2
1999 1
2003 2
2004 1
2005 2
2008 1
2009 1
2011 1
2014 1
2016 1
2021 1
2022 2
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Moore CB, Baltrusaitis K, Best BM, Moye JH, Townley E, Violari A, Heckman B, Buisson S, Van Solingen-Ristea RM, Capparelli EV, Marzinke MA, Lowenthal ED, Ward S, Krotje C, Milligan R, Agwu AL, Huang J, Cheung SYA, McCoig C, Yin DE, Roberts G, Crauwels H, Van Eygen V, Zabih S, Masheto G, Ounchanum P, Aurpibul L, Korutaro V, Gaur AH; IMPAACT 2017 Collaborators for the IMPAACT 2017 Team. Moore CB, et al. Among authors: buisson s. Lancet HIV. 2025 Mar;12(3):e191-e200. doi: 10.1016/S2352-3018(24)00344-8. Lancet HIV. 2025. PMID: 40049924 Clinical Trial.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, Yin DE, Agwu AL, Harrington C, Van Solingen-Ristea RM, McCoig CC, Adeyeye A, Kneebone J, Chounta V, Smith-Anderson C, Camacho-Gonzalez A, D'Angelo J, Bearden A, Crauwels H, Huang J, Buisson S, Milligan R, Ward S, Bolton-Moore C, Gaur AH; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Lowenthal ED, et al. Among authors: buisson s. Lancet HIV. 2024 Apr;11(4):e222-e232. doi: 10.1016/S2352-3018(23)00301-6. Lancet HIV. 2024. PMID: 38538161 Free PMC article. Clinical Trial.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH, Capparelli EV, Calabrese K, Baltrusaitis K, Marzinke MA, McCoig C, Van Solingen-Ristea RM, Mathiba SR, Adeyeye A, Moye JH, Heckman B, Lowenthal ED, Ward S, Milligan R, Samson P, Best BM, Harrington CM, Ford SL, Huang J, Crauwels H, Vandermeulen K, Agwu AL, Smith-Anderson C, Camacho-Gonzalez A, Ounchanum P, Kneebone JL, Townley E, Bolton Moore C; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Gaur AH, et al. Lancet HIV. 2024 Apr;11(4):e211-e221. doi: 10.1016/S2352-3018(23)00300-4. Lancet HIV. 2024. PMID: 38538160 Free PMC article. Clinical Trial.
Gene expression profiling in male genital lichen sclerosus.
Edmonds E, Barton G, Buisson S, Francis N, Gotch F, Game L, Haddad M, Dinneen M, Bunker C. Edmonds E, et al. Among authors: buisson s. Int J Exp Pathol. 2011 Oct;92(5):320-5. doi: 10.1111/j.1365-2613.2011.00779.x. Epub 2011 Jun 30. Int J Exp Pathol. 2011. PMID: 21718371 Free PMC article.
Forty-Eight Week Outcomes of a Site-Randomized Trial of Combined Cognitive Behavioral Therapy and Medication Management Algorithm for Treatment of Depression Among Youth With HIV in the United States.
Brown LK, Baltrusaitis K, Kennard BD, Emslie GJ, Chernoff M, Buisson S, Lypen K, Whiteley LB, Traite S, Krotje C, Knowles K, Townley E, Deville J, Wilkins M, Reirden D, Paul M, Beneri C, Shapiro DE; IMPAACT 2002 Team. Brown LK, et al. Among authors: buisson s. J Acquir Immune Defic Syndr. 2022 Nov 1;91(3):296-304. doi: 10.1097/QAI.0000000000003058. Epub 2022 Jul 20. J Acquir Immune Defic Syndr. 2022. PMID: 35839439 Free PMC article. Clinical Trial.
Cognitive Behavioral Therapy Factors Related to Outcomes in Depression Among Youth with HIV.
Kennard BD, Brown LK, Baltrusaitis K, Chernoff M, Emslie GJ, Jones J, Buisson S, Deville J, Wilkins M, Bunch A, Jackson CM, Beneri C, Shapiro DE; IMPAACT 2002 Team. Kennard BD, et al. Among authors: buisson s. Cognit Ther Res. 2024 Aug;48(4):781-790. doi: 10.1007/s10608-024-10474-0. Epub 2024 Mar 28. Cognit Ther Res. 2024. PMID: 39664885 Free PMC article.
Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.
Yang H, Buisson S, Bossi G, Wallace Z, Hancock G, So C, Ashfield R, Vuidepot A, Mahon T, Molloy P, Oates J, Paston SJ, Aleksic M, Hassan NJ, Jakobsen BK, Dorrell L. Yang H, et al. Among authors: buisson s. Mol Ther. 2016 Nov;24(11):1913-1925. doi: 10.1038/mt.2016.114. Epub 2016 Jun 6. Mol Ther. 2016. PMID: 27401039 Free PMC article.
Site-Randomized Controlled Trial of a Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United States.
Brown LK, Chernoff M, Kennard BD, Emslie GJ, Lypen K, Buisson S, Weinberg A, Whiteley LB, Traite S, Krotje C, Harriff L, Townley E, Bunch A, Purswani M, Shaw R, Spector SA, Agwu A, Shapiro DE; IMPAACT 2002 team. Brown LK, et al. Among authors: buisson s. J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):497-505. doi: 10.1097/QAI.0000000000002790. J Acquir Immune Defic Syndr. 2021. PMID: 34483297 Free PMC article. Clinical Trial.
24 results